Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases

British Journal of Cancer

Volumn 116, Issue 12, 2017, Pages 1558-1563

  Parakh, Sagun ^a,b   Park, John J ^c,d   Mendis, Shehara ^e   Rai, Rajat ^d,f   Xu, Wen ^g   Lo, Serigne ^d,f   Drummond, Martin ^d,f   Rowe, Catherine ^g   Wong, Annie ^g   McArthur, Grant ^g   Haydon, Andrew ^e   Andrews, Miles C ^a,b   Cebon, Jonathan ^a,b   Guminski, Alex ^d,f,h   Kefford, Richard F ^c,f,i   Long, Georgina V ^d,f,h   Menzies, Alexander M ^d,f,h   Klein, Oliver ^a,b   Carlino, Matteo S ^c,d,f  

^a AUSTIN HEALTH   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h Ryde and North Shore Hospitals   (Australia)

ⁱ MACQUARIE UNIVERSITY   (Australia)

Author keywords

anti PD1 therapy; brain metastases; corticosteroids; metastatic melanoma; nivolumab; pembrolizumab

Indexed keywords

B RAF KINASE; CORTICOSTEROID; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER SURGERY; DEMOGRAPHY; DISEASE CONTROL; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN NEOPLASMS; COMPLICATION; CRANIOTOMY; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIOSURGERY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SECONDARY; SURVIVAL RATE; SYMPTOM ASSESSMENT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIOTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOSURGERY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYMPTOM ASSESSMENT; YOUNG ADULT;

EID: 85020376894     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.142     Document Type: Article

References (34)

1. Ahmed K, Abuodeh Y, Echevarria M, Arrington J, Stallworth D, Hogue C, Naghavi A, Kim S, Kim Y, Patel B, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani N, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol 27(12): 2288-2294.
2. Ahmed K, Stallworth D, Kim Y, Johnstone P, Harrison L, Caudell J, Yu H, Etame A, Weber J, Gibney G (2015) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27(3): 434-441.
3. Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV (2014) Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120: 530-536.
4. Carlino MS, Fogarty GB, Long GV (2012) Treatment of melanoma brain metastases: a new paradigm. Cancer J 18: 208-212.
5. Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM (2017) Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer 75: 169-178.
6. Dossgg LL, Memula N (1982) The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys 8: 1131-1134.
7. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, Mckenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74: 5458-5468.
8. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688.
9. Dudnik E, Moskovitz M, Wollner M, Zer A, Bar J, Agbarya A, Idan T, Shechtman Y, Amna MA, Peled N (2016) 181P: Anti-PD-1 antibodies in non-small cell lung cancer (NSCLC): The real-life setting experience. J Thor Oncol 11: S136.
10. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50: 611-621.
11. Fife K, Colman M, Stevens G, Firth I, Moon D, Shannon K, Harman R, Petersen-Schaefer K, Zacest A, Besser M (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22: 1293-1300.
12. Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4): 256-265.
13. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7): 976-983.
14. Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28): 3193-3198.
15. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1): 23-34.
16. Liniker E, Menzies A, Kong B, Cooper A, Ramanujam S, Lo S, Kefford R, Fogarty G, Guminski A, Wang T (2016) Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology 5: e1214788.
17. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087-1095.
18. Margolin K, Ernstoff MS, Hamid O, Lawrence D, Mcdermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13: 459-465.
19. Margolin KA, Tawbi HA-H, Ernstoff MS, Hodi FS, Mcdermott DF, Edwards R, Avila A, Atkins MB (2015) A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. ASCO Annual Meeting Proceedings. J Clin Oncol 33: abstr TPS9080.
20. McArthur G, Maio M, Arance A, Nathan P, Blank C, Avril M, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28(3): 634-641.
21. Menzies A, Johnson D, Ramanujam S, Atkinson V, Wong A, Park J, Mcquade J, Shoushtari A, Tsai K, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2): 368-376.
22. Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15: e371-e381.
23. Park S, Dong H, Zhao W, Grams M, Liu X, Harrington S, Furutani K, Krco C, Olivier K, Markovic S (2014) PD-1 blockade enhances radiation therapy-induced abscopal effect. Int J Radiat Oncol Biol Phys 90: S57-S58.
24. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED (2015) PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3: 610-619.
25. Qian JM, Yu JB, Kluger HM, Chiang VL (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19): 3051-3058.
26. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L, Maio M, Di Giacomo AM (2014) Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118: 109-116.
27. Raizer JJ, Hwu W-J, Panageas KS, Wilton A, Baldwin DE, Bailey E, Von Althann C, Lamb LA, Alvarado G, Bilsky MH (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10: 199-207.
28. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu W-J, Weber JS (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315: 1600-1609.
29. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16: 908-918.
30. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, Mcneil C, Kalinka-Warzocha E (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320-330.
31. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, Mcneil C, Lotem M (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532.
32. Sridharan V, Schoenfeld JD (2015) Immune effects of targeted radiation therapy for cancer. Discov Med 19: 219-228.
33. Topalian SL, Sznol M, Mcdermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020-1030.
34. Weber JS, D'angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384.